Table 2.

EEC primary outcome.

Exposures	Nasal response	Results H2–H4	Results H0–H4
Birch allergen (V5)	Negative	12/30 (40.0%)	9/30 (30.0%)
	Positive	18/30 (60.0%)	21/30 (70.0%)
Placebo (V3)	Negative	30/30 (100.0%)	30/30 (100.0%)

The frequency of nasal responses with placebo (V3) versus birch allergen (V5), were statistically significant (p < .0001). During the H2–H4 time period, no participants reported nasal response with placebo (V3), while 18 participants (60%) experienced a rhinitis response to allergen (V5). Similar results were found for the H0–H4 time period, with rhinitis responses in 21 patients (70%) exposed to allergen versus 0 with placebo